Oxford Biomedica (LON:OXB) Now Covered by Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Oxford Biomedica (LON:OXB) in a research report sent to investors on Monday, MarketBeat reports. The firm issued a buy rating and a GBX 827 price target on the biopharmaceutical company’s stock.

OXB has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft raised their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a research note on Friday, January 9th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 950 price objective on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Oxford Biomedica currently has an average rating of “Moderate Buy” and a consensus target price of GBX 687.

Oxford Biomedica Trading Down 1.5%

LON:OXB opened at GBX 606 on Monday. The company has a market cap of £732.48 million, a PE ratio of -16.73 and a beta of 1.04. The company has a current ratio of 1.89, a quick ratio of 1.67 and a debt-to-equity ratio of 322.11. The company has a 50 day simple moving average of GBX 753.31 and a two-hundred day simple moving average of GBX 665.64. Oxford Biomedica has a 12 month low of GBX 232.50 and a 12 month high of GBX 952.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.